Clinical trials: Fatty Liver Disease, Nonalcoholic
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Non-alcoholic Fatty Liver Disease
Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD
This is a small preliminary study conducted to explore new methods for the potential of aiding in diagnosis of liver fibrotic disease as well as predicting disease progression.
- Trial name
- NCT02124577
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Hepatic Disease
Ketotifen in Non-Alcoholic Fatty Liver Disease Patients
The aim of this study is to investigate the safety and efficacy of using ketotifen in patients with NAFLD patients without cirrhosis
- Trial name
- NCT05616442
- Testing
- Ketotifen, Vitamin E
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Nonalcoholic Steatohepatitis
Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis
The purpose of the study is to evaluate whether Viusid, a nutritional supplement, in combination with diet and exercise improve the histological results (steatosis, necro-inflammatory activity and fibrosis) in comparison with…
- Trial name
- NCT00509418
- Testing
- Viusid, Hypocaloric Diet with controlled exercise
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
Non-alcoholic Steatohepatitis (NASH)
Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)
Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)
- Trial name
- NCT05423327
- Testing
- No Intervention
- Where
- 50 sites in United States, Brazil and 3 more
- Volunteers
- 5,311 people
- Sponsor
- Regeneron Pharmaceuticals
NAFLD, NASH - Nonalcoholic Steatohepatitis
Adipokine Genetic Variations in predictingNAFLD Progression to NASH in Egyptian Patients
Due to the limited data concerning Egyptian population. authors aimed to investigate the differentadipokine gene polymorphism related to non alcoholic fatty liver disease incidence, prognosis and progression to steotosis and also…
- Trial name
- NCT04561895
- Testing
- DNA extraction
- Where
- Egypt
- Volunteers
- 224 people
- Sponsor
- Cairo University
Nonalcoholic Fatty Liver Disease (NAFLD)
Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
The aim of this current study was to assess the therapeutic effects of perindopril and telmisartan for hypertensive patients with NAFLD and make comparison between the therapeutic effects of these two kind of drugs.
- Trial name
- NF-NAFLD (NCT02213224)
- Testing
- Perindopril, Telmisartan, Amlodipine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Type 2 Diabetes Mellitus, Metabolic Dysfunction-associated Steatotic Liver Disease
Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease (Version 3.0)
This study aims to explore the efficacy of CMNT, an intermittent energy restriction (iER) intervention, in managing Chinese adults with type 2 diabetes and non-alcoholic fatty liver disease.
- Trial name
- NCT07083336
- Testing
- CMNT diet
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- State Key Laboratory of Subhealth Intervention Technology
Fatty Liver
Weight Management in Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is one of the most common chronic liver diseases. The cause of NASH is not completely understood and currently there is no effective treatment for this disease.
- Trial name
- NCT00266019
- Testing
- Weight Management (diet, exercise, and behavior modification)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NASH - Nonalcoholic Steatohepatitis
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.
- Trial name
- NCT03912532
- Testing
- NGM282
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Nonalcoholic Fatty Liver Disease
Brown Adipose Tissue Activity and NAFLD Progression
This single-center, non-interventional observational study investigated the association between brown adipose tissue (BAT) activity and nonalcoholic fatty liver disease (NAFLD)-related clinical characteristics.
- Trial name
- NCT07825467
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Renmin Hospital of Wuhan University
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor).
- Trial name
- MIRNA (NCT04321031)
- Testing
- PF-06865571, PF-05221304
- Where
- 291 sites in United States, Bulgaria and 10 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Fatty Liver Disease
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment
Non-alcoholic fatty liver disease (NAFLD) has become a major health problem worldwide with an increasing prevalence ranging from 13% in Africa to 42% in South-East Asia.
- Trial name
- Fatty liver (NCT05694923)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Egypt
- Volunteers
- 55 people
- Sponsor
- Assiut University
Overweight and/or Obesity, Metabolic Syndrome
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss
This randomized, sham-controlled trial evaluates the efficacy and safety of ERCG plus optimized lifestyle intervention compared with sham procedure plus optimized lifestyle intervention in Chinese adults with overweight…
- Conditions
- Overweight and/or Obesity, Metabolic Syndrome, Nonalcoholic Fatty Liver Disease
- Trial name
- iWAIST-RCT (NCT07237750)
- Testing
- Endoscopic Radial Compression Gastroplasty, Optimized Lifestyle Intervention (OLI)
- Where
- 2 sites in China
- Volunteers
- 216 people
- Sponsor
- Liu Yan
Nonalcoholic Steatohepatitis
A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects
To evaluate the safety, tolerability, and immunogenicity of B1344 by single subcutaneous (s.c.) injection in healthy subjects
- Trial name
- NCT05655221
- Testing
- B1344
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
NASH - Nonalcoholic Steatohepatitis, NAFLD
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
This is a randomized, placebo-controlled, four-arm, double-blind study. Subjects will be randomized (1:1:1:1) to receive either a daily oral placebo solution or a daily oral dose of 0.5 mg, 2.5 mg or 5.0 mg Foralumab Solution for…
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAFLD, T2DM (Type 2 Diabetes Mellitus)
- Trial name
- NCT03291249
- Testing
- Foralumab, Omeprazole 20mg
- Sponsor
- Tiziana Life Sciences LTD
NAFLD, NASH - Nonalcoholic Steatohepatitis
The Franciscus Obesity NASH Study
The purpose of this study is to evaluate Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) changes in terms of steatosis and elasticity in patients with morbid obesity 1, 3 and 5 years after…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, Obesity, Morbid
- Trial name
- FONS (NCT05499949)
- Testing
- NASH screening, Cardiac dysfunction screening, Liver biopsy
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Franciscus Gasthuis
Hepatitis
Treating Nonalcoholic Steatohepatitis With Pioglitazone
Nonalcoholic steatohepatitis (NASH) is a common liver disease that resembles alcoholic hepatitis but occurs in persons who drink little or no alcohol.
- Trial name
- NCT00062764
- Testing
- Actos (Pioglitazone)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NASH - Nonalcoholic Steatohepatitis
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve Gastrectomy (VSG) with Iifestyle modification, followed for 12 months.
- Trial name
- NCT03587831
- Testing
- Vertical Sleeve Gastrectomy, Lifestyle Modification Counseling
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Nonalcoholic Steatohepatitis
Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis
The purpose of this study is to evaluate the effects of solithromycin on hepatic histology and biomarkers in patients with nonalcoholic steatohepatitis.
- Trial name
- NCT02510599
- Testing
- solithromycin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Melinta Therapeutics, Inc.